Skip to search boxSkip to navigationSkip to main content

Enhancing antitumor efficacy of heavily vascularized tumors by rambo virus through decreased tumor endothelial cell activation

  • Mitra Nair
    ,
  • Maninder Khosla
    ,
  • Yoshihiro Otani
    ,
  • Margaret Yeh
    ,
  • Flora Park
    ,
  • Toshihiko Shimizu
*Corresponding author for this work
  • University of Texas Health Science Center at Houston
    ,
  • Ohio State University
    ,
  • National Institutes of Health
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Vascularization is a common pathology for many solid tumors, and therefore anti-angiogenic strategies are being investigated as a therapeutic target for treatment. Numerous studies are also being conducted regarding the effects of oncolytic viruses, including Imlygic™, an FDA approved oncolytic herpes simplex virus-1 (oHSV) for the treatment of highly vascularized tumors such as Kaposi sarcoma (NCT04065152), and brain tumors. To our knowledge, the effects of combining oncolytic HSV with angiogenesis inhibition on endothelial cell activation has not been previously described. Here, we tested the effects of Rapid Antiangiogenesis Mediated By Oncolytic Virus (RAMBO), an oHSV which expresses a potent anti-angiogenic gene Vasculostatin on endothelial cell activation in heavily vascularized solid tumors. oHSV treatment induces endothelial cell activation, which inhibits virus propagation and oncolysis in adjacent tumor cells in vitro. Consistently, this was also observed in intravital imaging of intracranial tumor-bearing mice in vivo where infected tumor endothelial cells could efficiently clear the virus without cell lysis. Quantitative real-time PCR (Q-PCR), leukocyte adhesion assay, and fluorescent microscopy imaging data, however, revealed that RAMBO virus significantly decreased expression of endothelial cell activation markers and leukocyte adhesion, which in turn increased virus replication and cytotoxicity in endothelial cells. In vivo RAMBO treatment of subcutaneously implanted sarcoma tumors significantly reduced tumor growth in mice bearing sarcoma compared to rHSVQ. In addition, histological analysis of RAMBO-treated tumor tissues revealed large areas of necrosis and a statistically significant reduction in microvessel density (MVD). This study provides strong preclinical evidence of the therapeutic benefit for the use of RAMBO virus as a treatment option for highly vascularized tumors.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Article number

1040

Journal (Volume, Issue Number)

Cancers (Volume 12, Issue 4)

Publication milestones

  • Published - 04/2020

Publication status

Published - 04/2020

ISSN

2072-6694

Publication IDs

  • Scopus: 85083829480

Publication metrics

Metrics

Fractional count
1
Fractional count
0.06
Fractional count
15
Fractional count
0.94
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Social media
5
Citation count
16
Captures
15

Funding Details

Funding: This work was supported by Research Scholar Grants (RSG-19-185-01-MPC) from the American Cancer Society to J.Y.Y, by National Institute of Health (NIH) grants R01 NS064607, P01CA163205, R01 CA150153 to B.K, and by The Ohio State University Comprehensive Cancer Center (OSUCCC) and the NIH P30 CA016058) to R.S. and R.E.P. This work was supported by Research Scholar Grants (RSG-19-185-01-MPC) from the American Cancer Society to J.Y.Y, by National Institute of Health (NIH) grants R01 NS064607, P01CA163205, R01 CA150153 to B.K, and by The Ohio State University Comprehensive Cancer Center (OSUCCC) and the NIH P30 CA016058) to R.S. and R.E.P.
FundersFunding numbers
NIH
P01CA163205, R01 CA150153, R01 NS064607
Ohio State University Comprehensive Cancer Center LAPS
P30 CA016058
ACS
-